Drug Profile
Research programme: glycogen synthase kinase-3 inhibitors - Kemia
Latest Information Update: 26 Feb 2008
Price :
$50
*
At a glance
- Originator Kemia
- Class
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Mood disorders
Most Recent Events
- 22 Jun 2005 Preclinical trials in Affective disorders in USA (PO)
- 22 Jun 2005 Preclinical trials in Diabetes mellitus in USA (PO)